- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00932438
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab (DEBIRI)
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Concomitant Systemic Oxaliplatin, Fluorouracil and Leucovorin Chemotherapy, and Anti-Angiogenic Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina
- Hospital Italiano de Buenos Aires
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35805
- Clearview Cancer Center
-
-
California
-
Sacramento, California, United States, 95816
- Radiology Associates of Sacramento/Sutter Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Atlanta, Georgia, United States, 30342
- Northside Hospital/GA Cancer Specialists
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Mississippi
-
Tupelo, Mississippi, United States, 38801
- Hematology and Oncology Assoc. at Bridgeport
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University/Alvin J. Siteman Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center/Providence Cancer Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert Memorial Lutheran Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
- Patients over 18 years of age, of any race or sex, who have histologic or radiologic proof of colorectal cancer to the liver, who are able to give informed consent, will be eligible.
- Patients with at least one measurable liver metastases, with size > 1cm response evaluation criteria in solid tumors (RECIST)
- Patients with liver dominant disease defined as ≥80% tumor body burden confined to the liver
- Patients with patent main portal vein
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of < 2
- Life expectancy of > 3 months
- Non-pregnant with an acceptable contraception in premenopausal women.
- Hematologic function: absolute neutrophil count (ANC) ≥ 1.5 x 109/L, platelets ≥75 x109/L, international normalized ratio (INR) ≤1.3* (*If patient is on anticoagulants, they must be able to stop medication temporarily prior to TACE and must have INR ≤1.3 prior to receiving TACE) Adequate liver function as measured by: Total bilirubin ≤ 2.0mg/dl, alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤5 times upper limits of normal (ULN), albumin ≥2.5g/dl, Adequate Hemoglobin and Hematocrit as measured by (Male: for approximate 45 - 62%; and approximate Female: 37 - 48%) or Hemoglobin (Male: approximate 13 - 18 gm/dL Female: approximate 12 - 16 gm/dL). If patient is asymptomatic with Hemoglobin for male 10 to 12.9 or Female 9.5 to 11.9 and do not wish to be transfused they still will be eligible for treatment.
- Adequate renal function (creatinine ≤ 2.0mg/dl)
- Women of child bearing potential and fertile men are required to use effective contraception negative serum beta human chorionic gonadotropin (βHCG)
- Signed, written informed consent
- Patient is at least one month out from any treatment for Stage III colorectal cancer
Patient is at least one year out from any treatment for their Stage IV colorectal cancer.
- these patients should not be candidates for curative treatments, and will have recovered from any chemotherapeutic toxicities' they may have experienced."
- Less than 60% liver tumor replacement
Exclusion:
- "Any patient eligible for curative treatment (i.e. resection or radiofrequency ablation). Note: resectability is defined as a single tumor <5cm with adequate liver function defined: Total bilirubin ≤ 2.0mg/dl" non-resectability includes patients with greater than 6, tumors close to blood vessels, patients with hepatic-pulmonary shunting, or patients of poor performance"
- Active bacterial, viral or fungal infection within 72 hours of study entry
- Women who are pregnant or breast feeding
- Allergy to contrast media that cannot be managed with standard care (e.g. steroids), making magnetic resonance imaging (MRI) or computed tomography (CT) contraindicated.
- Presence of another malignancy with the exception of cervical carcinoma in situ and stage I basal or squamous carcinoma of the skin.
Any contraindication for hepatic embolization procedures:
- Large shunt as determined by the investigator (pretesting with TcMMA not required)
- Severe atheromatosis
- Hepatofugal blood flow
- Main portal vein occlusion (e.g. thrombus or tumor)
- Other significant medical or surgical condition, or any medication or treatment, that would place the patient at undue risk and that would preclude the safe use of chemoembolization or would interfere with study participation
- Patients with prior contraindications for the use of irinotecan therapy-this would include chronic inflammatory bowel disease and or bowel obstruction, history of severe hypersensitivity reactions to irinotecan hydrochloride, trihydrate, lactic acid or to any of the excipients of camptosar, severe bone marrow failure, history of Gilbert Syndrome or concomitant use with St. John's Wort
- Patients with prior contraindications for the use of fluorouracil, oxaliplatin, leucovorin or bevacizumab
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LC Beads loaded with Irinotecan and FOLFOX6
Device: LC Beads loaded with 100mg Irinotecan Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician |
Chemoembolization using LC beads loaded with 100mg Irinotecan
Other Names:
Oxaliplatin 85 mg/sqm, IV infusion every two weeks
Other Names:
Leucovorin 200 mg/sqm, IV infusion every two weeks
Other Names:
5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
Other Names:
Bevacizumab 5 mg/kg given at the discretion of the treating physician
Other Names:
|
Active Comparator: FOLFOX6 and Bevacizumab
Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
|
Oxaliplatin 85 mg/sqm, IV infusion every two weeks
Other Names:
Leucovorin 200 mg/sqm, IV infusion every two weeks
Other Names:
5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
Other Names:
Bevacizumab 5 mg/kg given at the discretion of the treating physician
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response
Time Frame: Months 2, 4 and 6
|
Tumor response will be determined using Modified Response Evaluation Criteria in Solid Tumors (mRECIST).
Response will classified as: Complete response - disappearance of all lesions; Partial response - at least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum of longest diameter or 30% reduction of arterial enhancement; Progressive disease - at least 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest longest diameter recorded since start of treatment or appearance of one or more new lesions greater than 1cm in size; Stable disease - neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter since start of treatment.
|
Months 2, 4 and 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Serious Adverse Events
Time Frame: First treatment through one year post treatment completion
|
Total number of serious adverse events that occurred in both Arms of the study.
|
First treatment through one year post treatment completion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Robert CG Martin, MD, PhD, University of Louisville
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Neoplastic Processes
- Colorectal Neoplasms
- Neoplasm Metastasis
- Colonic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Oxaliplatin
- Bevacizumab
- Leucovorin
- Irinotecan
Other Study ID Numbers
- DEBIRI # 09.0034
- UL2008.1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer With Metastases to the Liver
-
Liaoning Tumor Hospital & InstituteNot yet recruitingFor Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple MethodChina
-
Dana-Farber Cancer InstituteNational Cancer Institute (NCI); Pharmavite LLCRecruitingStage, Colon Cancer | Stage I-III Colon Cancer | Stage IV Colon Cancer With Resectable Liver MetastasesUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingColorectal Cancer | Colon Cancer | Liver Metastasis Colon Cancer | Adenocarcinoma of the Rectum | Colon Cancer Liver Metastasis | Adenocarcinoma of the ColonUnited States
-
National Cancer Institute (NCI)TerminatedMucinous Adenocarcinoma of the Rectum | Signet Ring Adenocarcinoma of the Rectum | Liver Metastases | Mucinous Adenocarcinoma of the Colon | Signet Ring Adenocarcinoma of the Colon | Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal CancerUnited States
-
Stanford UniversityNational Cancer Institute (NCI); Philips HealthcareCompletedColon Cancer | Liver MetastasesUnited States
-
RenJi HospitalNot yet recruitingColon Cancer Liver Metastases
-
Odense University HospitalSygehus Lillebaelt; Svendborg Hospital; Hospital of South West JutlandCompletedColon Cancer | Liver Metastases | Rectum CancerDenmark
-
University of MilanUniversity of BolognaCompletedMultiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.Colon Cancer | Colorectal Liver Metastases
-
University of ManchesterManchester University NHS Foundation Trust; The Christie NHS Foundation Trust; Perspect... and other collaboratorsUnknownCancer | Colorectal Cancer | Liver Metastasis Colon Cancer | Cancer MetastaticUnited Kingdom
-
University of California, San FranciscoTaiho Pharmaceutical Co., Ltd.; Sirtex MedicalCompletedRectal Cancer | Colon Cancer | Liver MetastasesUnited States
Clinical Trials on LC beads loaded with Irinotecan
-
Singapore General HospitalSinghealth FoundationCompletedColorectal Cancer MetastaticSingapore
-
Robert C. MartinM.D. Anderson Cancer Center; Thomas Jefferson University; University of LouisvilleCompletedLC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma (DEBDOX)Stage IV MelanomaUnited States
-
Yale UniversityNational Cancer Institute (NCI)CompletedLiver CancerUnited States
-
Fudan UniversityNot yet recruitingColorectal Cancer | Liver MetastasesChina
-
University of PittsburghBiocompatibles UK LtdCompletedHepatocellular CarcinomaUnited States
-
Cardiovascular and Interventional Radiological...CompletedNeoplasm Metastasis | Colorectal CarcinomaAustria
-
Yale UniversityBayer; Biocompatibles UK LtdCompletedHepatocellular Carcinoma | HepatomaUnited States
-
Nova Scotia Health AuthorityZimmer BiometCompletedSpinal Stenosis | Spondylolisthesis | Degenerative Lumbar Disc DiseaseCanada
-
Terumo Europe N.V.Universitaire Ziekenhuizen KU Leuven; Federation Francophone de Cancerologie...Completed
-
Taipei Physical Education CollegeCompleted